ILLUMINA, INC.
Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.
CAPITALIZATION 12/28/25
| ($ millions) | Amount | % |
|---|---|---|
| Total debt | – | – |
| Stockholders' equity | 2,723 | 100.0 |
| Total capitalization | 2,723 | 100.0 |
151,000,000 shares outstanding at 24 July 2026 (cover page of the 10-Q filed 31 July 2026).
LONG-TERM DEBT 12/28/25
| ($ millions) | Amount |
|---|---|
| Not tagged in XBRL |
CAPITAL STOCK 12/28/25
| Common shares authorized | 320,000,000 |
| Common shares issued | 201,000,000 |
| Treasury shares | 48,000,000 |
| Par or stated value per share ($) | 0.01 |
| Preferred stock ($ millions) | 0 |
| Outstanding at 7/24/26 | 151,000,000 |
DIVIDENDS DECLARED/PAID
| Fiscal year | Per share $ | Payout % |
|---|---|---|
| 2025 | – | – |
| 2024 | – | – |
| 2023 | – | – |
| 2023 | – | – |
| 2022 | – | – |
HISTORY AND BUSINESS
HISTORY: Incorporated in Delaware.
BUSINESS: Classified by the SEC under Standard Industrial Classification 3826, Laboratory Analytical Instruments. Large accelerated filer. Principal executive office: 5200 Illumina Way, San Diego, CA 92122. Fiscal year ends January 3. For a description of the business, see Item 1 of the latest 10-K.
CONSOLIDATED INCOME ACCOUNT, YEARS ENDED
| ($ millions) | 12/28/25 | 12/29/24 | 12/31/23 |
|---|---|---|---|
| Revenues | 4,343 | 4,372 | 4,504 |
| Cost of revenues | 1,473 | 1,511 | 1,760 |
| Gross profit | 2,870 | 2,861 | 2,744 |
| Research and development | 967 | 1,169 | 1,354 |
| Selling, general and administrative | 1,086 | 1,092 | 1,612 |
| Depreciation and amortization | 270 | 354 | 432 |
| Operating income | 807 | (833) | (1,069) |
| Interest expense | 101 | 100 | 77 |
| Income before income taxes | 1,086 | (1,179) | (1,117) |
| Income taxes | 236 | 44 | 44 |
| Net income | 850 | (1,223) | (1,161) |
| Earned per share, diluted ($) | 5.45 | (7.69) | (7.34) |
| Dividends per share ($) | – | – | – |
CONSOLIDATED BALANCE SHEET
| ($ millions) | 12/28/25 | 12/29/24 |
|---|---|---|
| Receivables, net | 854 | 735 |
| Inventories | 564 | 547 |
| Total current assets | 3,289 | 2,746 |
| Property, plant and equipment, net | 759 | 815 |
| Goodwill | 1,113 | 1,113 |
| Total assets | 6,644 | 6,303 |
| Total current liabilities | 1,585 | 1,547 |
| Stockholders' equity | 2,723 | 2,373 |
| Total liabilities and equity | 6,644 | 6,303 |
TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)
| Fiscal year ended | Revenues | Oper. income | Net income | Net margin % | EPS diluted $ | Div. per share $ | Oper. cash flow | Capital expend. | Free cash flow | Total assets | Total liabilities | Total debt | Stockholders' equity | ROE % | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/28/25 | 4,343 | 807 | 850 | 19.6 | 5.45 | – | 1,079 | 148 | 931 | 6,644 | 3,921d | – | 2,723 | 31.2 | – |
| 12/29/24 | 4,372 | (833) | (1,223) | -28.0 | (7.69) | – | 837 | 128 | 709 | 6,303 | 3,930d | – | 2,373 | -51.5 | – |
| 12/31/23 | 4,504 | (1,069) | (1,161) | -25.8 | (7.34) | – | 478 | 195 | 283 | 10,111 | 4,366d | – | 5,745 | -20.2 | – |
| 1/1/23 | 4,584 | (4,179) | (4,404) | -96.1 | (28.00) | – | 392 | 286 | 106 | 12,252 | 5,653d | – | 6,599 | -66.7 | – |
| 1/2/22 | 4,526 | (123) | 762 | 16.8 | 5.04 | – | 545 | 208 | 337 | 15,217 | 4,477d | – | 10,740 | 7.1 | – |
| 1/3/21 | 3,239 | 580 | 656 | 20.3 | 4.45 | – | 1,080 | 189 | 891 | 7,585 | 2,891d | 1,184 | 4,694 | 14.0 | 0.25 |
| 12/29/19 | 3,543 | 985 | 1,002 | 28.3 | 6.74 | – | 1,051 | 209 | 842 | 7,316 | 2,703d | 1,141 | 4,613 | 21.7 | 0.25 |
| 12/30/18 | 3,333 | 883 | 826 | 24.8 | 5.56 | – | 1,142 | 296 | 846 | 6,959 | 3,114d | 1,997 | 3,758 | 22.0 | 0.53 |
| 12/31/17 | 2,752 | 606 | 726 | 26.4 | 4.92 | – | 875 | 310 | 565 | 5,257 | 2,508d | 1,192 | 2,749 | 26.4 | 0.43 |
| 1/1/17 | 2,398 | 587 | 463 | 19.3 | 3.07 | – | 779 | 260 | 519 | 4,281 | 2,011d | 1,058 | 2,197 | 21.1 | 0.48 |
Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.
REGISTRANT:
ILLUMINA, INC.
CIK 1110803 · EIN 33-0804655
PRINCIPAL OFFICE:
5200 Illumina Way, San Diego, CA 92122
Tel.: 8582024500
INCORPORATED:
Delaware
INDUSTRY (SEC SIC CODE):
3826 · Laboratory Analytical Instruments
FILER STATUS:
Large accelerated filer
LATEST ANNUAL REPORT:
10-K for period ended 12/28/25, filed 12 February 2026
FORMER NAMES:
ILLUMINA INC
Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/12/26) · 10-K FY2024 (filed 2/12/25) · 10-K FY2023 (filed 2/16/24) · 10-K FY2021 (filed 2/18/22) · 10-K FY2020 (filed 2/17/21) · 10-K FY2019 (filed 2/11/20) · 10-K FY2018 (filed 2/12/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.
Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.